iBio

iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. It operates through the Biopharmaceuticals and Bioprocessing segments. The Biopharmaceuticals segment involves molecule discovery, development, and licensing activities. The Bioprocessing segment includes contract development and manufacturing services for recombinant proteins. The company was founded on April 17, 2008 and is headquartered in Bryan, TX.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q1 2025

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets. The company was founded on April 17, 2008 and is headquartered in San Diego, CA.

Investors in iBio (NYSEAMERICAN:IBIO) remain curious about hedging potential bets on the shares. So, how should investors looking to make a speculative play on iBio stock judge its merits?

IBIO Stock Remains a Spec Play on a Potential Vaccine

iBio, Inc.: Time To Back Up Its Multi-Bagger Position

Inovio Pharmaceuticals

Novavax

Shares of companies with COVID-19 vaccine candidates were mixed in volatile trading Monday, after the promising results from trials of vaccine candidates from Pfizer Inc.

IBio's stock soars, but Novavax and Inovio stocks fall amid news on other COVID-19 vaccine candidates

A recent study out of the UK suggests that immunity following infection might wear off just a few months after infection. That should throw a wet blanket on any remaining hopes of a V-shaped economic recovery.

Is IBIO Stock Even A Bet Worth Taking?

iBio stock success depends on a binary event, so the thesis is very simple. Buy it now on good faith or watch it from the sidelines.

Bulls in Charge of iBio Stock Since March

During the initial strike of the novel coronavirus, IBIO stock was a huge gamble. But with the stakes raised, the underlying biotech firm could turn out to be instrumental.

3 Reasons to Invest in, Not Trade iBio

Asset prices don't go up in a straight line, even if the company shows promise. Use the dip in IBIO stock now to get in at a favorable price.

Big Catalysts Are Just Around the Corner for iBio Stock

It appears iBio may have to settle for an assist in the race for a Covid-19 vaccine, but that gives investors little reason to buy IBIO stock. 
The post The Curtain Is Coming Down on IBIO appeared first on InvestorPlace.

The Curtain Is Coming Down on IBIO

Fears of a second coronavirus wave have Covid-19 focused biotech stocks surging again. So where does IBIO stock fit into the mix?

IBM Partnership and Rising Covid-19 Cases Are Lifting iBio Stock

Buying a stock because it could be part of the solution to coronavirus is a risky way to play an already volatile market. IBIO stock's weak financials make it all the more dependent on coronavirus drugs to deliver.

Right Now, iBio Stock Is Even More Risky Than You Might Have Thought

IBIO stock is on a bull run of epic proportions but there is little to suggest the biotech company can come up with a Covid-19 vaccine.
The post Why iBio Is an Excellent Pandemic Spec Play appeared first on InvestorPlace.

Why iBio Is an Excellent Pandemic Spec Play

AIM ImmunoTech Inc

Evoke Pharma

LiveXLive Media

Cheap stocks are effectively Wall Street's casino.

5 Cheap Stocks to Buy for $10 or Less

iBio stock is still a buy but it needs to land contracts with some major vaccine developers as we get closer to a Covid-19 vaccine
The post iBio Is in a Healthy Position With Covid-19 Vaccine Push appeared first on InvestorPlace.
More From InvestorPlace
		
					
				
					Why Everyone Is Investing in 5G All WRONG				
			
					
				
					America’s #1 Stock Picker Reveals His Next 1,000% Winner				
			
					
				
					Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company				
			
					
				
					Radical New Battery Could Dismantle Oil Markets

iBio Is in a Healthy Position With Covid-19 Vaccine Push

Shares of iBio Inc. IBIO, +3.87% rocketed 64% on heavy volume in premarket trading Friday, as the biotherapeutics and contract manufacturing company is set to be added to the Russell 2000 RUT, +1.69% and Russell 3000 RUA, +1.18% indexes.

IBio's stock rockets on heavy volume after Russell index inclusion

NEW YORK, June  26, 2020  (GLOBE NEWSWIRE) --  iBio, Inc.  (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics innovator and contract manufacturing organization, today announced that it will be added to the Russell 2000® and Russell 3000® indexes as part of this year's reconstitution. The additions will be made effective after the U.S. markets open on June 29, 2020.

iBio to be Added to the Russell 2000® and Russell 3000® Indexes

iBio Granted 18 Months of Free Access to IBM’s Clinical Trial Management System iBio Granted 18 Months of Free Access to IBM’s Clinical Trial Management System

iBio Selected by IBM Watson Health for the use of IBM Clinical Development Solution at No Cost to help Support clinical COVID-19 Vaccine Candidates

IBIO stock has drawn a good deal of interest of late. It's a speculative play with the potential to reward optimistic investors handsomely.

3 Pros, 3 Cons For Buying iBio Stock Right Now

The enthusiasm surrounding iBio stock is warranted since the company is yet to deliver a viable, commercially successful vaccine.
The post Coronavirus Hype Is Boosting iBio Shares to Unrealistic Levels appeared first on InvestorPlace.

Coronavirus Hype Is Boosting iBio Shares to Unrealistic Levels

As companies race to develop a Covid-19 vaccine, IBIO stock investors are likely paying too much for a potential manufacturing contract.
The post Early Shareholders Can Win If iBio Gets a Vaccine Contract appeared first on InvestorPlace.

Early Shareholders Can Win If iBio Gets a Vaccine Contract

Unlike other vaccine stocks, iBio has the tech it needs to scale up manufacturing of its candidate. That makes IBIO stock a buy here.

FastPharming Tech Makes iBio Stock a Buy

For investors in search of a novel coronavirus play, IBIO’s puny capitalization and continued one-trick pony press releases are fair warning and increasingly, so is the price chart
The post More Suspect PR and Now One More Reason to Walk Away From IBIO Stock appeared first on InvestorPlace.
More From InvestorPlace
		
					
				
					Why Everyone Is Investing in 5G All WRONG				
			
					
				
					Top Stock Picker Reveals His Next 1,000% Winner				
			
					
				
					The 1 Stock All Retirees Must Own				
			
					
				
					Look What America’s Richest Family Is Investing in Now

More Suspect PR and Now One More Reason to Walk Away From IBIO Stock

The price of iBio stock could double, if not triple in value on successful trials, and on the potential for FDA approval in the near term.
The post Why iBio Stock Could Triple on Successful Vaccine Trials appeared first on InvestorPlace.

Why iBio Stock Could Triple on Successful Vaccine Trials

Alpha Pro Tech

Co-Diagnostics

Carvana

Moderna

Shopify

Wayfair

These seven A- and B-rated names are some of the top risky stocks to buy for enterprising investors. Here's what you should know about each company.

7 Risky Stocks That Are Worth a Gamble

With the underlying vaccination business, IBIO stock could make you rich. At the same time, if things go awry, it could make you poor in a hurry.

It’s the Right Price but the Wrong Time to Invest in iBio

iBio's production facility could be used to manufacture a Covid-19 vaccine. It remains to be seen if IBIO stock will be a star or a bust.

News for iBio Stock (IBIO)